Literature DB >> 3871202

Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.

M J Griffith, L Breitkreutz, H Trapp, E Briet, C M Noyes, R L Lundblad, H R Roberts.   

Abstract

Two structurally different forms of activated human Factor IX (Factor IXa alpha and IXa beta) have been previously reported to have essentially identical clotting activity in vitro. Although it has been shown that activated Factor IX Chapel Hill, an abnormal Factor IX isolated from the plasma of a patient with mild hemophilia B, and normal Factor IXa alpha are structurally very similar, the clotting activity of activated Factor IX Chapel Hill is much lower (approximately fivefold) than that of normal Factor IXa beta. In the present study we have prepared activated Factor IX by incubating human Factor IX with calcium and Russell's viper venom covalently bound to agarose. Fractionation of the activated Factor IX by high-performance liquid chromatography demonstrated the presence of both Factors IXa alpha and IXa beta. On the basis of active site concentration, determined by titration with antithrombin III, the clotting activities of activated Factor IX Chapel Hill and IXa alpha were similar, but both activities were less than 20% of the clotting activity of Factor IXa beta. Activated Factor IX activity was also measured in the absence of calcium, phospholipid, and Factor VIII, by determination of the rate of Factor X activation in the presence of polylysine. In the presence of polylysine, the rates of Factor X activation by activated Factor IX Chapel Hill, Factor IXa alpha, and Factor IXa beta were essentially identical. We conclude that the clotting activity of activated Factor IX Chapel Hill is reduced when compared with that of Factor IXa beta but essentially normal when compared with that of Factor IXa alpha.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871202      PMCID: PMC423385          DOI: 10.1172/JCI111694

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Chromatography of human prothrombin complex or dextran sulphate agarose.

Authors:  D S Pepper; C Prowse
Journal:  Thromb Res       Date:  1977-11       Impact factor: 3.944

2.  The purification and mechanism of action of human antithrombin-heparin cofactor.

Authors:  R D Rosenberg; P S Damus
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

3.  A simplified method for cyanogen bromide activation of agarose for affinity chromatography.

Authors:  S C March; I Parikh; P Cuatrecasas
Journal:  Anal Biochem       Date:  1974-07       Impact factor: 3.365

4.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

5.  Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom.

Authors:  P A Lindquist; K Fujikawa; E W Davie
Journal:  J Biol Chem       Date:  1978-03-25       Impact factor: 5.157

6.  Activation of human factor IX (Christmas factor).

Authors:  R G Di Scipio; K Kurachi; E W Davie
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

7.  Comparison of amino acid sequence of bovine coagulation Factor IX (Christmas Factor) with that of other vitamin K-dependent plasma proteins.

Authors:  K Katayama; L H Ericsson; D L Enfield; K A Walsh; H Neurath; E W Davie; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

8.  A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S.

Authors:  R G Di Scipio; M A Hermodson; S G Yates; E W Davie
Journal:  Biochemistry       Date:  1977-02-22       Impact factor: 3.162

9.  Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.

Authors:  K S Chung; D A Madar; J C Goldsmith; H S Kingdon; H R Roberts
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

10.  Genetic variants of hemophilia B: detection by means of a specific PTC inhibitor.

Authors:  H R Roberts; J E Grizzle; W D McLester; G D Penick
Journal:  J Clin Invest       Date:  1968-02       Impact factor: 14.808

View more
  4 in total

1.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

2.  Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction.

Authors:  Bruce Sullenger; Rebecca Woodruff; Dougald M Monroe
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

3.  Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.

Authors:  A H Schmaier; L D Dahl; A J Rozemuller; R A Roos; S L Wagner; R Chung; W E Van Nostrand
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

4.  A candidate activation pathway for coagulation factor VII.

Authors:  Tina M Misenheimer; Kraig T Kumfer; Barbara E Bates; Emily R Nettesheim; Bradford S Schwartz
Journal:  Biochem J       Date:  2019-10-15       Impact factor: 3.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.